Comprehensive Insights on GALAXY Study in CIRCULATE-Japan

The resubmission included an analysis of the phase 3 CARES-310 study, which reported favorable overall survival with the combination therapy in uHCC.

Oncology pharmacist Jagoda Misniakiewicz, PharmD, discusses the potential efficacy and safety profile of fruquintinib in patients with metastatic CRC.

Results from the INNATE trial showed the use of sotigalimab to be a safe and efficacious regimen for patients with rectal cancer.

Surgical oncologists from Cleveland Clinic discuss the National Accreditation Program for Rectal Cancer and its aim to improve patient outcomes.

The approval is based on results from the global phase 3 FRESCO-2 trial, which demonstrated improvement in OS in patients with refractory metastatic colorectal cancer.

NO-CUT trial data show that DRFS was maintained when non-operative management was used in patients with pMMR locally advanced rectal cancer.